Psychiatric genetics research, as exemplified by the DISC1 gene, aspires to inform on mental health etiology and to suggest improved strategies for intervention. DISC1 was discovered in 2000 through the molecular cloning of a chromosomal translocation that segregated with a spectrum of major mental illnesses in a single large Scottish family. Through in vitro experiments and mouse models, DISC1 has been firmly established as a genetic risk factor for a spectrum of psychiatric illness. As a consequence of its protein scaffold function, the DISC1 protein impacts on many aspects of brain function, impacting both neurosignalling and neurodevelopment. DISC1 is a pathfinder for understanding psychopathology, brain development, signaling and circuitry. Though much remains to be learnt and understood, potential targets for drug development are starting to emerge, and in this review, we will discuss the 10 years of research that has helped us understand key roles of DISC1 in psychiatric disease.
DISC1: on the path to pathfinder
In the original Scottish family, a remarkable 70% of those with the DISC1 gene disruption [1] had a psychiatric diagnosis of schizophrenia (SZ), bipolar disorder (BP) or major depressive disorder (MDD) (Fig. 1) , and all tested had deficits in the amplitude of the eventrelated potential P300 that characterizes SZ and BP [2] . This broad spectrum of disorder is consistent with recent epidemiological evidence, which points to a substantial sharing of genetic risk between SZ and BP and thus, a blurring of diagnostic and genetic boundaries for these disorders [3, 4] . Subsequent DISC1 genetic studies have provided evidence for both regulatory and coding mutations in DISC1 that are associated with SZ, BP, MDD, schizoaffective disorder and autism, and with quantitative variation in behavior and brain function within the normal range (reviewed in [5] [6] [7] [8] ). Multiple, ultra-rare mutations, apparently unique to patients, have also been identified [9, 10] . Although these follow on studies have been crucial in establishing a general role for DISC1 in risk of psychiatric illness, its status as a translational pathfinder rests less on the genetic evidence and more on our growing understanding of DISC1 biology. In this review, we will summarize what the past 10 years have taught us about the biology and function of DISC1.
DISC1: where, when and how?
In 2005, critical advances in understanding the role of DISC1 came from two independent, but complementary, directions. Millar et al [11] described a different chromosomal rearrangement, this time disrupting the phosphodiesterase 4B (PDE4B) gene in two cousins, one with SZ and the other psychosis. Moreover, they showed that PDE4B interacted dynamically with DISC1, likely modulating cAMP levels in a protein kinase A phosphorylation-dependent fashion [11] . PDE4 activity is linked to memory formation in the fly (cognate dunce mutation), to mood disorder in the mouse (via knock out studies) and is a direct target for rolipram, a non-selective PDE4 inhibitor with antipsychotic and antidepressant activity in pre-clinical models [12] . Kamiya et al [13] reported that in utero application of short hairpin loop RNA oligonucleotides (shRNA) targeting mouse Disc1 resulted in reduced migration of neurons out of the sub-ventricular zone to the cortical plate, accompanied by altered cell polarity and reduced dendritic arborisation. These studies demonstrated for the first time a direct role for DISC1 both in neurosignalling and in early brain development, in harmony with current concepts of schizophrenia [14] .
DISC1 is widely expressed not only in the brain, most highly during fetal neurogenesis and in the adult hippocampus, but also in other tissues. DISC1 shows little sequence similarity to other known proteins and the three-dimensional structure is unsolved, but bioinformatic analysis predicts multiple C-terminal coiled coil domains and a disordered N-terminal domain [5, 8] . Moreover, DISC1 forms dimers, octamers and higher order states, a process that is influenced by the common Ser704Cys amino acid sequence variant. This variant impacts on protein binding, at least for the interacting partner NUDEL1, and may have pathological implications, as insoluble aggregates of DISC1 are associated with chronic psychiatric disease [15, 16] . Critically, biochemical and expression studies establish DISC1 as a multifunctional, neurodevelopmentally regulated scaffold, or 'hub', protein [5, 7, 8, 17, 18] . It is these features of DISC1 which explain the connection between psychiatric genetics and neuroscience, setting out a pathway for translation of therapies from the bench to the clinic. Interested readers are directed to Bradshaw and Porteous [7] and Soares et al. [8] for recent detailed reviews of the genetic, biochemical and biophysical evidence supporting these connections.
Genetics and biology of the DISC1 pathway
The scaffold function of DISC1 helps resolve the genetics paradox. The set of DISC1 interacting partners are enriched for proteins known to have a role in neurodevelopment, neurosignalling, cytoskeletal, centrosomal and synaptic function [17, 8] . Through an interaction with the amyloid precursor protein APP, DISC1 is potentially involved in neurodegeneration [19] , and high molecular pathway connectivity links DISC1 to the causal Huntington's Disease protein, HTT [18] . Thus, DISC1 has the potential to simultaneously affect a wide range of plausible risk processes in disease susceptibility [5, 8, 20, 21] . Genetic association studies point to the effect of common, non-coding variants in DISC1 and genes encoding several DISC1 partners, including PDE4B, PDE4D, NDE1, NDEL1, LIS1, FEZ1, PCM1 and TNIK (reviewed in [7] ). The interplay between single nucleotide polymorphism (SNP) variants within DISC1 affects the risk of SZ and BP [22] , and several papers have demonstrated a genetic interplay between DISC1 and NDE1 [23] . An epistatic interaction between the DISC1 Ser704Cys variant and NDEL1 affects the risk for SZ and manifests at the cellular level as altered neurite extension [24] . Finally, epistasis occurs between DISC1 and CIT as well as NDEL1 and CIT, as validated in part by functional brain imaging measures of hippocampal engagement and working memory in healthy controls [25] . Moreover, common cis-variants of DISC1 alter the expression levels of the DISC1 gene by up to 20% of normal [26] . These modest reductions of DISC1 gene expression levels may exert subtle, but pervasive effects on neurodevelopment, neurophysiology and neural circuitry through the scaffold function of DISC1. Common, non-coding variants in DISC1, PDE4B, PDE4D and NDE1 are transcriptional modulators of cAMP signaling, cytoskeletal, synaptogenic, neurodevelopmental and sensory perception proteins [26] . This set of regulated proteins is significantly enriched for current targets of psychiatric drug development [26] . Thus, there is a combined impact of rare, highly penetrant variants and of common, low penetrant gene variants within the DISC1 pathway affecting the manifestation of psychiatric illness, cognition and brain function. Of further consideration is the recent evidence for as many as 50 different DISC1 isoforms, with dramatic differences in their preand post-natal brain expression profiles, and for the impact of common DISC1 genetic variants on relative isoform abundance [27] . Follow on studies from the same group have confirmed that when expressed in vitro the predicted truncated version of DISC1 binds to native DISC1 [28] . As predicted [8] , these putative truncated forms of DISC1 do not bind NDEL1 under the conditions used, nor did they bind PDE4B, but binding to FEZ1 and GSK3β was retained [28] . These results lend weight to earlier evidence from the same group for reduced expression of NUDEL, FEZ1 and LIS1 in schizophrenia, which was potentiated by the common DISC1 Ser704Cys polymorphism [29] . Replication of the experimental findings with respect to short isoforms of DISC1 protein in post-mortem materials and in vivo models will now be important as they may point to important mechanisms for DISC1-mediated developmental regulation. It is premature to judge the net impact of genetic variation within the DISC1 pathway on variation within the normal range of human behaviour, or on the elevated risk and spectrum of mental illness, but given the number of conditions that can arise as a consequence of DISC1 mutations the concept of DISCopathies may have utility and validity. Moreover, biological studies lend significant weight to the proposition that DISC1 participates in key neuronal processes (Fig. 2) .
Modeling DISC1-mediated brain circuitry and human psychopathology in the laboratory mouse
With the notable exception referred to above [27] [28] [29] [30] , access to well-characterized sample sets of fetal and adult human brain tissue is a major limitation in biological psychiatry. Fortunately, many different laboratory mouse models of Disc1 are now available that can at least partially compensate for the lack of human samples and help model the role of DISC1 [6, 31, 32] . Interested readers are referred to the recent article by Kelly and Brandon [32] who provide a comprehensive review of mouse models for the study of DISC1 and DISC1 interactors. Each model provides insights into cellular and molecular mechanisms, but a key feature worth emphasizing is how the observed behavioral phenotypes can be related back to the spectrum of psychotic and mood disorder observed in the original Scottish pedigree [2] ( Fig. 1) . Thus, deficits in both schizophrenia-associated phenotypes (e.g. prepulse inhibition) and those related to mood disturbance (e.g. forced swim test) were observed in a model overexpressing a truncated form of DISC1 [33] . Similarly, depression-related phenotypes were prominent in an ENU-induced amino acid substitution variant Gln31Leu, whereas a Leu100Pro substitution mutant showed more schizophrenia-associated abnormalities [34] . The Leu100Pro mutation has also been recently shown to modulate the developmental pattern of NRXN1 and NRXN3 gene expression [35] , two genes linked primarily to autism, but also to schizophrenia.
Understanding how DISC1 influences neuronal circuitry depends upon being able to modulate DISC1 expression in both a temporally and a spatially specific manner. Conditional knockout mice are not yet available, but modulation of DISC1 in a temporally and spatially specific manner has been achieved by generation of transgenic mice over expressing a truncated form of DISC1 under the control of an inducible CaMKII promoter [36] [37] [38] . The caveat for this mouse model being that the impact is limited to pyramidal neurons in the cortex and both pyramidal and granule neurons in the hippocampus. Transient knock down of Disc1, limited by direct injection of sHRNA constructs to the ventricular zone at the mid-embryonic stage, was shown to affect the prenatal and perinatal pyramidal neuron lineage in the prefrontal cortex [39] . Histological abnormalities were observed perinatally, but neither robust neurochemical nor behavioral phenotypes. Schizophrenia is typically diagnosed in late adolescence or early adulthood, so it was intriguing to note that in the Disc1 knockdown mouse model phenotypes relevant to schizophrenia, including disturbed dopaminergic neurotransmission and interneuron deficits in the cortex, plus several behavioral changes, such as deficits in prepulse inhibition and working memory, became apparent in young adulthood [39] .
DISC1 biology and neurodevelopment
Having demonstrated, at least in part, the validity of these experimental constructs in the mouse as models for human DISC1 variations, it is important to tease apart the mechanisms of DISC1 action (Fig. 2) . Biochemical studies have confirmed DISC1 interaction with LIS1, NDEL1, NDE1 and PCM1, all components of the microtubule-associated motor complex [5, 7, 31, 32] . These proteins are also involved in neurodevelopment processes, consistent with the early demonstration in mice that DISC1 plays a fundamental role in corticogenesis, especially radial neuronal migration and dendritic arborization [13] . In support of this, the DISC1 interacting proteins PCM1, BBS, CAMDI, Dixdc1 and APP are all involved in radial neuronal migration in the cortex [19, [40] [41] [42] . Moreover, DISC1 was elegantly shown to determine the proliferation and fate of neural progenitors through interaction with GSK3β and regulation of β-catenin activity [43] . More recently, Ishizuka et al. [44] reported that in mice, phosphorylation of DISC1 at Ser710 acts as a switch between progenitor proliferation and post-mitotic neuronal migration: unphosphorylated DISC1 regulates canonical Wnt signaling via an interaction with GSK3β and Ser710 phosphorylation enhances DISC1-BBS1 binding, possibly sequestering DISC1 from modulating Wnt / β-catenin activity. The emerging picture is of multiple DISC1 protein interactions regulating and coordinating neurodevelopmental processes in the cerebral cortex. DISC1 regulates neuronal migration and dendritic arborization in the CA1 and the dentate gyrus of the hippocampus [21, [45] [46] [47] [48] [49] . Whereas knockdown of Disc1 generally leads to delayed migration and less arborization, the opposite is true of newborn neurons in the adult dentate gyrus, suggesting that the key action of DISC1 is to regulate the tempo of migration [45] . That said, these demonstrations of cellular function have yet to conclusively identify the underlying molecular mechanisms.
DISC1 biology and neurosignalling
Cyclic AMP signalling regulates multiple brain processes, and by hydrolysing cAMP, the phosphodiesterases (PDEs) play a critical role. The Gln31Leu and Leu100Pro amino acid substitution mutations in the mouse [34] are components of PDE4 binding sites [50] , reduce the strength of the DISC1/PDE4B interaction, and for the Gln31Leu mice only, reduce PDE4B cAMP hydrolysis activity in the brain, consistent with altered DISC1/PDE4 function relating directly to their reported behavioural abnormalities [34, 50] . A modulatory role of another key DISC1 interactor, GSK3β, has also been implicated in cAMP-dependent activation of PDE4 [51] . Indeed, in mice carrying the Gln31Leu and Leu100Pro mutations, PDE4 and GSK3 activities synergise to modulate behavior [52, 53] . Moreover, both DISC1 mutations reduce the strength of the interaction with GSK3, as with PDE4 [52, 53] . Thus the phenotypes of mice carrying the Gln31Leu and Leu100Pro mutations are likely due, in part, to dysregulated pathways resulting from altered DISC1/PDE4 and DISC1/GSK3 interaction and function. It is critical for understanding the functions of DISC1 in psychiatric illnesses that these pathways are identified. Altered β-catenin and Wnt signaling has already been implicated [43] . Another clue is provided by the identified interaction between DISC1/PDE4 and the LIS1/NDE1/NDEL1 complex [54] . Within this complex, DISC1/PDE4 modulates phosphorylation of NDE1 at position Thr131 by cAMP-dependent protein kinase A (PKA) [55] . Thr131 is located in the binding interface for LIS1 and PDE4 [56] . Phosphorylation of this site reduces LIS1 binding, but promotes NDEL1 binding, and by implication, regulates the function of the complex as a whole [55] .
DISC1 is expressed in dendritic spines [54] where it associates with the post-synaptic density [34] and the pre-synapse [57] (Fig. 2) . DISC1 determines the tempo of spine and synapse development, the rate of acquisition of intrinsic excitability, and the development of functional synapses in the adult mouse brain [45] . In cultured mouse neurons, DISC1 modulates spine density and the number of miniature excitatory postsynaptic currents, with simultaneous effects upon cell surface expression of the GluR1 AMPA receptor subunit [58] . Moreover, mice carrying the Gln31Leu and Leu100Pro mutations display significantly reduced spine density [59] suggesting that dysregulated synapse development may contribute to their behavioural phenotypes.
The underlying mechanisms likely involve several of the DISC1 binding partners also identified at the post synaptic density (PSD), including PDE4 [34] and the LIS1/NDE1/ NDEL1 complex [54, 56] , but we currently have the most information about the interaction with Kal-7 [58] and TNIK [57] (Fig. 2) .
Kal-7 is a GDP/GTP exchange factor for Rac1 that modulates dendritic spines in response to NMDA receptor activity. DISC1 complexes simultaneously with Kal-7 and the PSD scaffold protein PSD-95 to modulate Rac1 activity, and there is evidence that these associations are regulated by NMDA receptor signalling [58] . Thus, it has been proposed that DISC1 modulates NMDA receptor-dependent Rac1 activity via Kal-7 to regulate spine function, and that this may be a pathological mechanism in schizophrenia [58] .
TNIK modulates Wnt signaling [60] and binds Rap2 to control neuronal properties including spine density [61] . DISC1 binds and inhibits TNIK. In neurons, this decreases the levels of the PSD proteins GluR1, stargazin and PSD-95 [57] . Moreover, TNIK knockdown decreases expression of these proteins and additionally reduces expression of GluR2, GluR3 and the NMDA receptor subunit NR2B, in parallel decreasing the amplitude of AMPA receptor miniature excitatory postsynaptic currents [57] . By contrast, DISC1 knockdown increases expression of GluR1, GluR2, GluR3 and TNIK, but reduces PSD-95 and stargazin levels. DISC1 and TNIK are thus essential for dynamic regulation of crucial post-synaptic proteins, including glutamate receptors. Interestingly, in a cell culture model measuring outputs via micro electrode arrays, TNIK, but not DISC1, knockdown profoundly dysregulated neural network development [62] .
NMDA receptor hypofunction is widely held to be a significant contributory pathological factor in schizophrenia [63] . The behaviour and pharmacological responses of mice engineered to have reduced expression of the NMDA receptor subunit NR1 make them an interesting model for schizophrenia [64] . There is emerging evidence that NMDA receptor function is directly linked to DISC1 as these mice display reduced dendritic spine density and decreased synaptic DISC1 expression [65] . Moreover, NMDA receptor antagonists decrease DISC1 expression, inducing overextended migration of newborn neurons, an abnormality that is rescued by DISC1 overexpression [66] . Given that we now have a raft of evidence supporting the relevance of the DISC1 pathway to the etiology of major mental illness, including an emerging evidence base for an influence on the NMDA receptor, does this mean that DISC1 is a good target for drug development?
Drugging DISC1: the challenges and opportunities
Those who suffer from major mental illness are poorly served by current drug treatments. In the last 50 years there have been few, if any, fundamental innovations in antipsychotics or antidepressants; many patients respond poorly, if at all, and many of these medications have serious side effects [67] . To date, translational research in schizophrenia has relied heavily on pharmacological models of dysregulated dopaminergic or glutamatergic signalling [68] , but genetic models are coming to the fore, including a mouse model that overexpresses the striatal D2-receptor [69] and a model with a partial NR1 knockout that results in reduced NMDA expression [64] and has now been shown to have reduced synaptic DISC1 [65] . That said, the construct validity of these models is modest. The neurodevelopmental, circuitry and behavioral abnormalities reported in a range of Disc1 mouse models suggests they could have great potential for translational studies of major mental illness. Disc1 mutant mice display a range of behavioural phenotypes that model relevant aspects of schizophrenia and mood disorder, which can be rescued by treatment with classical anti-psychotics and antidepressants [34] . Critically, early work demonstrates that relevant phenotypes can be modulated by PDE4 or GSK3 inhibition, which we know are mechanistically linked to the DISC1 pathway and thus offer novel therapeutic mechanisms and targets [34, 53] . These latter insights are essential as we contemplate screening for new clinically useful compounds across a wide spectrum of unmet mental health needs, and critically, show the absolute need to understand the biology of the DISC1 pathway in great detail (see below). Furthermore, the developmental nature of schizophrenia and related conditions raises the question of when to treat and how to prevent their appearance [14] . At least partial answers may come soon from refined conditional 'knock out' and 'knock in' studies in Disc1 mutant mouse models. But, more fundamentally, which, or indeed how many, of the functional consequences of DISC1 offer the best and most tractable targets for drug development or intervention? DISC1 is not 'druggable' in the conventional sense: it does not fall into any of the 'preferred' classes of targets, overwhelmingly ion channels, G-protein coupled receptors, metabolic enzymes and kinases. But the phosphodiesterases continue to be a major target for drug development in relation to CNS, cardiovascular and inflammatory disorders [12] . The trick here will be to find a way in which the DISC1-PDE4 interaction can be selectively modulated both temporally and spatially, to circumvent the emetic and other limiting downsides of direct inhibition of PDE4 [70] . The identification of GSK3β as a DISC1 interactor [43] highlights again the Wnt signaling pathway as a target for drug development, as does the link from DISC1 through Girdin to the AKT1/mTor pathway [44, 46] . This link between DISC1 and the AKT1/mTOR pathway brings into focus the role of lithium (or lithium-like molecules) in the treatment of bipolar disorder. Thus, for PDE4, GSK3β and AKT1/mTOR there is the attractive possibility of 'peering over the shoulder of others' working within the inflammatory, cancer and cardiovascular fields to identify molecules which selectively modulate these pathways, with the added constraint that these therapies must cross the blood-brain barrier. Finally, as a kinase known to function at the synapse, modulation of TNIK is also an attractive translational target [57] .
Will modulation of the DISC1 pathway be relevant only to those carrying highly penetrant mutations? This is unlikely to be the situation, given the evidence that common variants impact on multiple current targets relevant for psychiatric drug development [26] . Taken together, and despite the 'unfavourable' start point of DISC1 itself, there are reasonable grounds for optimism that through the discovery of the DISC1 gene and the DISC1 interactome, we have a novel and promising set of opportunities for 'conventional' drug development in psychiatry. There are technical, safety and efficacy considerations to consider with all of these approaches, but the possibility of identifying mechanisms for treating these devastating disorders makes this an absolute scientific and clinical imperative.
A more challenging, if potentially more valid, approach would be to rework the question and take a genomically-informed, systems approach to stratified medicine. This means thinking of the DISC1 complex as the 'target' in both time and space [21] . It means developing physiological read outs and developing small molecules and/or biologics to restore and maintain homeostatic balance, first in model systems and then clinical studies. None of this will prove easy or come quickly, but if we are not to see this as an opportunity, where else should we look?
Caveats and limitations
By meeting the criteria for causality [20] , DISC1 has provided a useful inroad into the biological understanding of other psychiatric risk genes and pathways, connecting 'bottom up' genetics and genomics to the 'top down' pharmacology, neurodevelopment, neurosignaling and neural circuitry -in short, helping to establish and promote an integrated systems neurobiology approach. But there are caveats and limitations, which are summarized in Box 1.
Future challenges and directions
The recent demonstration of a phosphorylation mediated, developmental switch in DISC1 function [44] signals a new level of necessary enquiry. It raises the question of whether other forms of post-translational modification are critical in modulating the role of DISC1. Multiple mouse models are now available and have proved instructive [32] , but a complete 'null' (either constitutive or regulatable) mutant and humanized models that recapitulate the t(1;11) as well as other disease associated mutations and variants will be valuable. For circuitry studies, rat models offer anatomical size advantages over the mouse and are now amenable to genetic [71] and optogenetic engineering [72] . For behavioral drug screening, the zebrafish has obvious appeal and is already proving promising for complex behavioural phenotypes of potential relevance to psychiatry [73, 74] . Arguably, the most valuable model to be developed will be patient-derived somatic cells carrying defined DISC1 mutations or variants reprogrammed to create specific cell types of defined neuronal lineage [75, 76] . Only once this full panoply of models is available can we realistically bridge the gap between basic and applied research. Box 2 summarises some of the outstanding questions for the DISC1 field over the next decade (to be reiterated in similar fashion for other robust genetic candidates in psychiatry).
To conclude, the first 10 years of DISC1 research has unveiled through diverse experimental approaches rich seams of evidence for fundamental roles in psychiatry and neuroscience. The next 10 are set to be even more exciting, if challenging, as we seek to refine our knowledge and understanding, satisfy our curiosity, and contribute in a practical way to understanding and modifying brain development, human behavior and mental illness. 
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Outstanding Questions
• What is the full spectrum of functional variation in the DISC1 gene and DISC1 interactors?
• How do genetic variants in the DISC1 pathway impact on psychopathology, behaviour and cognition? Is the concept of DISCopathies valid and useful?
• What are the biophysical properties of DISC1 and the DISC1 complex and how are these affected by common and rare genetic variants?
• How is DISC1 transcription and isoform expression regulated throughout development and in adult neuronal cell lineages?
• What is the nature of the DISC1 complex over the developmental time-course and at different sub-cellular locations?
• How is DISC1 modified by phosphorylation and other post-translation mechanisms, and with what functional consequences?
• What are the canonical and non-canonical functions of DISC1?
• How do these functions affect normal and aberrant development and behavior?
Box 2
Future directions
• Modelling DISC1 clinical mutations and common variants in human cell culture by neuralising reprogrammed fibroblasts.
• Humanising the laboratory mouse and other tractable animal species.
• Combining cell-culture-based and in vivo models to refine our molecular and cellular understanding of DISC1 function during development, at the synapse, and in brain signaling and circuitry.
• Testing for phenotypic rescue through genetic and chemical (small molecule) screens.
• Modulating the biophysical properties of aberrant DISC1 and DISC1 complexes.
• Translating these findings into improved strategies for diagnosis, prognosis and treatment by adapting treatments developed for other disciplines that target proteins known to interact with DISC1. The schema is a conceptual hierarchy linking DISC1 and its binding partners (yellow box) to their cellular localization (purple box), the functions affected by their loss or mutation (blue box), and the psychiatric disorders shown to be linked to DISC1 function (red box).
